14M Genomics and EORTC and announce first results from their collaboration on tumor profiling

November 16, 2015

Cambridge, UK: 16 November 2015. 14M Genomics ("14MG") and The European Organisation for Research and Treatment of Cancer ("EORTC") today announce the delivery of initial genomic mutation analyses conducted on newly diagnosed cancer patients as part of the EORTC Screening Patients for Efficient Clinical Trial Access (SPECTA) programme.

The first SPECTA project, SPECTAcolor, focuses on the diagnosis and treatment of colorectal cancer. Following its launch in 2013, it has been implemented in over 30 clinical centres in 11 European countries, with nearly 800 patients recruited. Clinical samples from many of these patients have now been analysed across hundreds of genomic regions using a sophisticated proprietary analytical and annotation pipeline (GABRIEL™) developed by 14MG. This tool rapidly and reproducibly processes cancer genomic data to generate patient-specific tumour genomic profiles. These results have been reported directly back to the participating physicians through the company's customised web-based portal (RAPHAEL™), which can guide enrolment of patients into biomarker-led clinical trials.

Linkage of these genomic profiles to disease progression and therapeutic response will form a valuable and growing reference resource to develop and guide optimal therapy for future cancer patients.

The EORTC aims to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. It also contributes to the development of new drugs and diagnostic tests in partnership with the pharmaceutical and the diagnostic industry. The collaboration with 14MG will now allow information on the genetic make-up of patients' tumours to be provided directly to participating oncologists, enabling rapid identification of treatment options and enrolment of patients into suitable clinical studies.

Alan Schafer, Chief Executive of 14MG, said, "We are delighted to announce delivery of the first patient tumour genomic profiles in our collaboration with the EORTC, its clinical centres and investigators. These profiles have been successfully delivered through our proprietary analytical and reporting pipeline, comprising the linked GABRIEL™ and RAPHAEL™ components, and demonstrate a critical step forward in allowing personalised patient tumour assessment, and enrolment into clinical trials that are most appropriate for their profile."

Dr Vassilis Golfinopoulos, Medical Director of the EORTC, said, "We are excited that our collaboration with 14MG has led to the successful generation of genomic data through application of the company's state-of-the-art sequencing and analytical technologies. As we expand our SPECTA programme, starting with SPECTAlung, specialising in thoracic tumours, and SPECTAbrain, for patients with tumours arising in the central nervous system, we look forward to a continued collaboration with 14MG on genomic profiling of these patients in readiness for clinical trial enrolment."

Further information:

EORTC
Vassilis Golfinopoulos
Medical Director EORTC
Headquarters

About 14M Genomics

14M Genomics aims to become a European leader in the provision of clinical genomics services and clinical decision support tools, which will inform the diagnosis, prognosis and treatment of cancer. The company employs state-of-the-art sequencing and analytical tools, coupled with an in-depth understanding of cancer biology, to reveal associations between tumour genomics and the clinical path of the individual patient. 14MG aims to work together with the oncology community, academic institutions and pharmaceutical partners to improve the lives of cancer patients. http://www.14mg.co.uk

About the EORTC

The European Organisation for the Research and Treatment of Cancer (EORTC) brings together European cancer clinical research experts from all disciplines for trans-national collaboration. Both multinational and multidisciplinary, the EORTC Network comprises more than 2,500 collaborators from all disciplines involved in cancer treatment and research in more than 300 hospitals in over 30 countries. Through translational and clinical research, the EORTC offers an integrated approach to drug development, drug evaluation programs and medical practices. EORTC Headquarters, a unique pan European clinical research infrastructure, is based in Brussels, Belgium, from where its various activities are coordinated and run. http://www.eortc.org

European Organisation for Research and Treatment of Cancer

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.